Skip to main content
Year archive

Pluri Inc. — 2020 filings

All 215 regulatory filings released by Pluri Inc. (PLUR) in 2020, sourced directly from the official regulator.

215 Filings
2020 Period
2020 filings (215)
Filing Released Lang
Enters Collaboration with Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated with COVID-19 Program to Mexico
Regulatory Filings
2020-12-29 English
Enters Collaboration with Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated with COVID-19 Program to Mexico
Report Publication Announcement
2020-12-29 English
FORM 8-K-presentation on DMC Recommendation Following Interim Analysis of its Phase III CLI Study
Regulatory Filings
2020-12-09 English
FORM 8-K-presentation on DMC Recommendation Following Interim Analysis of its Phase III CLI Study
Report Publication Announcement
2020-12-09 English
Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
Regulatory Filings
2020-12-09 English
Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
Report Publication Announcement
2020-12-09 English
CURRENT REPORT
Regulatory Filings
2020-12-09 English
Director's Dealing 2020
Director's Dealing
2020-12-01 English
8K-nitial interim results from its Phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery
Regulatory Filings
2020-11-18 English
8K-nitial interim results from its Phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery
Report Publication Announcement
2020-11-18 English
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
Regulatory Filings
2020-11-18 English
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting
Report Publication Announcement
2020-11-18 English
CURRENT REPORT
Regulatory Filings
2020-11-18 English
Form 10-Q For the quarterly period ended September 30, 2020
Interim / Quarterly Report Q1 2021
2020-11-06 English
Form 10-Q For the quarterly period ended September 30, 2020
Report Publication Announcement
2020-11-06 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2021
2020-11-05 English
Director's Dealing 2020
Director's Dealing
2020-11-03 English
Director's Dealing 2020
Director's Dealing
2020-10-29 English
World Experts in Infectious Diseases & Critical Care Form Pluristem’s COVID-19 Steering Committee
Board/Management Information
2020-10-20 English
World Experts in Infectious Diseases & Critical Care Form Pluristem’s COVID-19 Steering Committee
Report Publication Announcement
2020-10-20 English
Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
Regulatory Filings
2020-10-13 English
Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study
Report Publication Announcement
2020-10-13 English
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
Regulatory Filings
2020-10-08 English
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
Regulatory Filings
2020-10-08 English
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
Investor Presentation
2020-10-07 English
Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel
Regulatory Filings
2020-10-07 English
CURRENT REPORT
Regulatory Filings
2020-10-07 English
AMENDMENT NO.2 TO SCHEDULE 13G
Major Shareholding Notification
2020-10-05 English
Director's Dealing 2020
Director's Dealing
2020-10-01 English
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
Regulatory Filings
2020-10-01 English
Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event
Report Publication Announcement
2020-10-01 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-29 English
Director's Dealing 2020
Director's Dealing
2020-09-25 English
Director's Dealing 2020
Director's Dealing
2020-09-24 English
expects to complete enrollment of its Phase II patients suffering from severe COVID-19 in the first quarter of 2021.
Regulatory Filings
2020-09-16 English
expects to complete enrollment of its Phase II patients suffering from severe COVID-19 in the first quarter of 2021.
Legal Proceedings Report
2020-09-16 English
CURRENT REPORT
Regulatory Filings
2020-09-15 English
Pluristem CEO Issues Shareholder Update
Management Reports
2020-09-15 English
Pluristem CEO Issues Shareholder Update
Report Publication Announcement
2020-09-15 English
FORM 10-K For the fiscal year ended June 30, 2020
Annual Report FY 2020
2020-09-11 English
FORM 10-K For the fiscal year ended June 30, 2020
Report Publication Announcement
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Regulatory Filings
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Regulatory Filings
2020-09-11 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Regulatory Filings
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIALOWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIALOWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2020-09-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Regulatory Filings
2020-09-11 English
ANNUAL REPORT
Annual Report FY 2020
2020-09-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-10 English
Director's Dealing 2020
Director's Dealing
2020-09-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2020-09-10 English
PSTI S8 September 2020 2016 Plan
Capital/Financing Update
2020-09-10 English
PSTI S8 September 2020 2016 Plan
Report Publication Announcement
2020-09-10 English
PSTI S8 September 2020 2019 Plan
Share Issue/Capital Change
2020-09-10 English
PSTI S8 September 2020 2019 Plan
Report Publication Announcement
2020-09-10 English
REGISTRATION STATEMENT
Registration Form
2020-09-09 English
REGISTRATION STATEMENT
Registration Form
2020-09-09 English
8K-FDA has Cleared COVID-19 Expanded Access Program for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome caused by COVID-19
Regulatory Filings
2020-08-27 English
8K-FDA has Cleared COVID-19 Expanded Access Program for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome caused by COVID-19
Report Publication Announcement
2020-08-27 English
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
Regulatory Filings
2020-08-27 English
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
Report Publication Announcement
2020-08-27 English
CURRENT REPORT
Regulatory Filings
2020-08-27 English
Announces End of Patient Enrollment in its Phase I Hematology Study
Regulatory Filings
2020-08-19 English
Announces End of Patient Enrollment in its Phase I Hematology Study
Report Publication Announcement
2020-08-19 English
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19
Regulatory Filings
2020-08-17 English
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19
Report Publication Announcement
2020-08-17 English
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany-FORM 8-K
Regulatory Filings
2020-08-10 English
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany-FORM 8-K
Regulatory Filings
2020-08-10 English
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
Regulatory Filings
2020-08-10 English
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
Report Publication Announcement
2020-08-10 English
CURRENT REPORT
Regulatory Filings
2020-08-10 English
Director's Dealing 2020
Director's Dealing
2020-08-03 English
Director's Dealing 2020
Director's Dealing
2020-07-30 English
Director's Dealing 2020
Director's Dealing
2020-07-29 English
Director's Dealing 2020
Director's Dealing
2020-07-28 English
Regulatory Filings 2020
Regulatory Filings
2020-07-24 English
Regulatory Filings 2020
Regulatory Filings
2020-07-22 English
Regulatory Filings 2020
Regulatory Filings
2020-07-22 English
8k-Pluristem CEO Issues Shareholder Update on Clinical Programs
Regulatory Filings
2020-07-21 English
8k-Pluristem CEO Issues Shareholder Update on Clinical Programs
Report Publication Announcement
2020-07-21 English
Pluristem CEO Issues Shareholder Update on Clinical Programs
Management Reports
2020-07-21 English
Pluristem CEO Issues Shareholder Update on Clinical Programs
Report Publication Announcement
2020-07-21 English
CURRENT REPORT
Regulatory Filings
2020-07-21 English
Entered into an Open Market Sale Agreement with Jefferies LLC
Capital/Financing Update
2020-07-17 English
Entered into an Open Market Sale Agreement with Jefferies LLC
Report Publication Announcement
2020-07-17 English
FORM S-3-Shelf
Capital/Financing Update
2020-07-17 English
FORM S-3-Shelf
Report Publication Announcement
2020-07-17 English
CURRENT REPORT
Regulatory Filings
2020-07-16 English
REGISTRATION STATEMENT
Registration Form
2020-07-16 English
Director's Dealing 2020
Director's Dealing
2020-07-07 English
Annual Meeting Results
AGM Information
2020-07-02 English
Annual Meeting Results
AGM Information
2020-07-02 English
CURRENT REPORT
Regulatory Filings
2020-07-01 English
Director's Dealing 2020
Director's Dealing
2020-06-29 English
Director's Dealing 2020
Director's Dealing
2020-06-29 English
AMENDMENT NO. 1 TO SC 13G
Major Shareholding Notification
2020-06-29 English
PSTI 8K COVID Clinical Site Enrollments
Regulatory Filings
2020-06-11 English
PSTI 8K COVID Clinical Site Enrollments
Report Publication Announcement
2020-06-11 English
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
Regulatory Filings
2020-06-11 English
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
Report Publication Announcement
2020-06-11 English
CURRENT REPORT
Regulatory Filings
2020-06-11 English
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
Regulatory Filings
2020-06-03 English
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
Report Publication Announcement
2020-06-03 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 29, 2020
Proxy Solicitation & Information Statement
2020-05-26 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 29, 2020
Proxy Solicitation & Information Statement
2020-05-26 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 29, 2020
AGM Information
2020-05-26 English
Immediate Report of Meeting
AGM Information
2020-05-26 English
annual meeting on the date 29/06/2020 ,proxy-Amended
Proxy Solicitation & Information Statement
2020-05-24 English
annual meeting on the date 29/06/2020 ,proxy-Amended
Proxy Solicitation & Information Statement
2020-05-24 English
annual meeting on the date 29/06/2020 ,proxy-Amended
AGM Information
2020-05-24 English
convening annual meeting on the date 29/06/2020 ,proxy
Proxy Solicitation & Information Statement
2020-05-24 English
convening annual meeting on the date 29/06/2020 ,proxy
Proxy Solicitation & Information Statement
2020-05-24 English
convening annual meeting on the date 29/06/2020 ,proxy
AGM Information
2020-05-24 English
Regulatory Filings 2020
Regulatory Filings
2020-05-21 English
ANNUAL MEETING OF STOCKHOLDERS ,JUNE 29, 2020, PROXY CARD
Proxy Solicitation & Information Statement
2020-05-21 English
ANNUAL MEETING OF STOCKHOLDERS ,JUNE 29, 2020, PROXY CARD
Proxy Solicitation & Information Statement
2020-05-21 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 29,2020
Proxy Solicitation & Information Statement
2020-05-21 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 29,2020
Proxy Solicitation & Information Statement
2020-05-21 English
DEFINITIVE ADDITIONAL MATERIALS
Regulatory Filings
2020-05-20 English
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2020-05-20 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 29, 2020
Proxy Solicitation & Information Statement
2020-05-19 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 29, 2020
Regulatory Filings
2020-05-19 English
AMENDED PRELIMINARY 14A.
Regulatory Filings
2020-05-18 English
Regulatory Filings 2020
Regulatory Filings
2020-05-18 English
8K Compassionate Use Update
Regulatory Filings
2020-05-14 English
8K Compassionate Use Update
Regulatory Filings
2020-05-14 English
Pluristem Provides 28-Day Follow Up for Ventilator- Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
Earnings Release Q2 2020
2020-05-14 English
Pluristem Provides 28-Day Follow Up for Ventilator- Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
Report Publication Announcement
2020-05-14 English
Regulatory Filings 2020
Regulatory Filings
2020-05-14 English
CURRENT REPORT
Regulatory Filings
2020-05-14 English
10Q For the quarterly period ended March 31, 2020
Interim / Quarterly Report Q3 2020
2020-05-12 English
10Q For the quarterly period ended March 31, 2020
Report Publication Announcement
2020-05-12 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2020
2020-05-11 English
K-8-U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
Regulatory Filings
2020-05-08 English
K-8-U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
Report Publication Announcement
2020-05-08 English
U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
Investor Presentation
2020-05-08 English
U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
Report Publication Announcement
2020-05-08 English
CURRENT REPORT
Regulatory Filings
2020-05-08 English
Prospectus Supplement
Capital/Financing Update
2020-05-06 English
Prospectus Supplement
Report Publication Announcement
2020-05-06 English
PROSPECTUS SUPPLEMENT
Prospectus
2020-05-06 English
Pluristem Therapeutics entered into a securities purchase agreement with two institutional investors
Regulatory Filings
2020-05-06 English
Pluristem Therapeutics entered into a securities purchase agreement with two institutional investors
Report Publication Announcement
2020-05-06 English
Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
Share Issue/Capital Change
2020-05-05 English
Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
Report Publication Announcement
2020-05-05 English
CURRENT REPORT
Regulatory Filings
2020-05-05 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS ON 29.6.20
Proxy Solicitation & Information Statement
2020-05-01 English
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS ON 29.6.20
Proxy Solicitation & Information Statement
2020-05-01 English
8K-Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
Regulatory Filings
2020-04-30 English
8K-Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
Report Publication Announcement
2020-04-30 English
Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
Call Transcript
2020-04-30 English
Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
Regulatory Filings
2020-04-30 English
PRELIMINARY PROXY STATEMENT
Regulatory Filings
2020-04-30 English
CURRENT REPORT
Regulatory Filings
2020-04-30 English
EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
Capital/Financing Update
2020-04-30 English
EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
Report Publication Announcement
2020-04-30 English
SCHEDULE 13G
Major Shareholding Notification
2020-04-29 English
The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020
Regulatory Filings
2020-04-27 English
The European Investment Bank (EIB), EU Delegation to Israel, the Israel Innovation Authority, and Pluristem Cordially Invite the Public to an Online Signing Ceremony on April 30, 2020
Report Publication Announcement
2020-04-27 English
PSTI 8K EIB Funding Announecement
Regulatory Filings
2020-04-24 English
PSTI 8K EIB Funding Announecement
Report Publication Announcement
2020-04-24 English
Pluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies
Capital/Financing Update
2020-04-24 English
Pluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies
Regulatory Filings
2020-04-24 English
CURRENT REPORT
Regulatory Filings
2020-04-24 English
8-K -Pluristem Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program
Regulatory Filings
2020-04-13 English
8-K -Pluristem Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program
Report Publication Announcement
2020-04-13 English
Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program
Regulatory Filings
2020-04-13 English
Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program
Report Publication Announcement
2020-04-13 English
CURRENT REPORT
Regulatory Filings
2020-04-13 English
8K: Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
Regulatory Filings
2020-04-07 English
8K: Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
Report Publication Announcement
2020-04-07 English
Reports Preliminary Data from its COVID-19 Compassionate Use Program „h All treated patients were in Intensive Care Units (ICU) on ven
Earnings Release Q1 2020
2020-04-07 English
Reports Preliminary Data from its COVID-19 Compassionate Use Program „h All treated patients were in Intensive Care Units (ICU) on ven
Report Publication Announcement
2020-04-07 English
CURRENT REPORT
Regulatory Filings
2020-04-07 English
PSTI - 8-K - COVID-19 3 Patients PR
Regulatory Filings
2020-03-31 English
PSTI - 8-K - COVID-19 3 Patients PR
Report Publication Announcement
2020-03-31 English
CURRENT REPORT
Regulatory Filings
2020-03-30 English
Treated First Three COVID-19 Patients in Israel under Compassionate Use
Regulatory Filings
2020-03-30 English
Treated First Three COVID-19 Patients in Israel under Compassionate Use
Report Publication Announcement
2020-03-30 English
FORM 8K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,press release which includes a letter from i
Regulatory Filings
2020-03-26 English
FORM 8K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers,press release which includes a letter from i
Report Publication Announcement
2020-03-26 English
CURRENT REPORT
Regulatory Filings
2020-03-26 English
PSTI - CEO Letter COVID 19 and Phase III Clinical Trials Status
Environmental & Social Information
2020-03-26 English
PSTI - CEO Letter COVID 19 and Phase III Clinical Trials Status
Report Publication Announcement
2020-03-26 English
Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells
Regulatory Filings
2020-03-17 English
Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells
Report Publication Announcement
2020-03-17 English
8K:Pluristem and Charitי University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
Regulatory Filings
2020-03-12 English
8K:Pluristem and Charitי University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
Report Publication Announcement
2020-03-12 English
Pluristem and Charitי University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
Regulatory Filings
2020-03-12 English
Pluristem and Charitי University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19
Report Publication Announcement
2020-03-12 English
CURRENT REPORT
Regulatory Filings
2020-03-12 English
FORM 8-K, BARDA RESPONSE
Regulatory Filings
2020-03-03 English
FORM 8-K, BARDA RESPONSE
Report Publication Announcement
2020-03-03 English
Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
Regulatory Filings
2020-03-03 English
Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal
Regulatory Filings
2020-03-03 English
CURRENT REPORT
Regulatory Filings
2020-03-03 English
Pluristem Therapeutics CEO Issues Shareholder Update
Earnings Release Q2 2020
2020-02-10 English
Pluristem Therapeutics CEO Issues Shareholder Update
Report Publication Announcement
2020-02-10 English
PSTI 10Q December 31 2019
Interim / Quarterly Report H1 2020
2020-02-07 English
PSTI 10Q December 31 2019
Report Publication Announcement
2020-02-07 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2020
2020-02-06 English
In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.
Investor Presentation
2020-02-03 English
In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.
Report Publication Announcement
2020-02-03 English